Vanda Pharmaceuticals (VNDA) to Release Quarterly Earnings on Wednesday

Vanda Pharmaceuticals (NASDAQ:VNDA) is projected to release its earnings data before the market opens on Wednesday, February 5th. Analysts expect Vanda Pharmaceuticals to post earnings of ($0.11) per share and revenue of $51.91 million for the quarter.

Vanda Pharmaceuticals Price Performance

Shares of NASDAQ VNDA opened at $4.31 on Tuesday. Vanda Pharmaceuticals has a 1 year low of $3.46 and a 1 year high of $6.75. The stock has a market capitalization of $251.32 million, a P/E ratio of -15.39 and a beta of 0.74. The company has a 50-day moving average price of $4.70 and a 200-day moving average price of $4.95.

Analysts Set New Price Targets

VNDA has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Vanda Pharmaceuticals in a research note on Tuesday, January 28th. StockNews.com initiated coverage on Vanda Pharmaceuticals in a research report on Tuesday, January 28th. They issued a “hold” rating for the company.

Insiders Place Their Bets

In other news, Director Stephen Ray Mitchell sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $5.17, for a total transaction of $25,850.00. Following the completion of the sale, the director now owns 44,857 shares in the company, valued at $231,910.69. This trade represents a 10.03 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 8.90% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.